Clinicial services firm OXB has rolled out an expedited development and GMP manufacturing offering for adeno-associated virus (AAV) and lentiviral (LV) vectors, aimed at biotech clients facing tight timelines or constrained financing.
For AAV programmes the fast-track route can reduce an industry-standard timeline of roughly 15 months to as little as seven months. OXB attributes the acceleration to its high-performance, plug‑and‑play inAAVate™ platform, which lowers the number of bespoke development steps while delivering high titres and consistent scale-relevant performance, supported by in‑house accelerated analytical development and qualification.
The LentiVector™ fast-track pathway cuts typical lentiviral development windows of 12–18 months to as little as nine months by leveraging platform datasets and advanced analytics and by progressing directly from scale‑down models into GMP manufacture. OXB also cites time savings from integrating vector design, production, purification and fill‑finish under a single programme.
The company launched the service in response to client demand and positions it as a cost‑effective option for programmes that need to hit clinical or regulatory gates more quickly. OXB said the offering extends the global reach of its proprietary platforms and reinforces its role in viral vector development and manufacturing.
"For emerging cell and gene therapy companies, viral vector development and manufacture represents a frequent bottleneck to clinical readiness, and issues can delay critical clinical milestones. The launch of our fast-track offering will make our proprietary inAAVate™ and LentiVector™platforms accessible to a wider range of clients who are looking for an expedited route to GMP manufacture and the clinic, cutting industry standard development timelines by up to 50%." Dr Sébastien Ribault, Chief Business Officer, said.
OXB highlighted that the new service will be delivered from its development and manufacturing sites across Oxfordshire, Lyon and Strasbourg in Europe and Bedford, MA and Durham, NC in the US.
